SuperGen, Inc. Announces Achievement Of $20 Million Dacogen(TM) (Decitabine) Injection Milestone
DUBLIN, Calif., May 26 /PRNewswire-FirstCall/ -- SuperGen, Inc. announced today that the first commercial shipment of Dacogen(TM) (decitabine) injection was released by MGI PHARMA, INC. to wholesale drug distributors earlier this week. Under the terms of its exclusive worldwide licensing agreement with MGI PHARMA, SuperGen has achieved the $20 million commercialization milestone. Additionally, SuperGen will earn a royalty on worldwide net sales starting at 20% and escalating to a maximum of 30%.
Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen's portfolio includes Orathecin(TM) (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent(R) (pentostatin for injection), Mitomycin, and Surface Safe(R) cleaner. In addition, a number of aurora-A, tyrosine kinase and DNA methyltransferase inhibitors are under development. For more information about SuperGen, please visit http://www.supergen.com.
Contacts: SuperGen Noonan Russo Timothy L. Enns Sharon Weinstein S.V.P., Corporate Communications Director of Investor Relations & Business Development Tel: (925) 560-0100 x111 Tel: (212) 845-4271 E-mail: email@example.com E-mail: firstname.lastname@example.orgSuperGen, Inc.
CONTACT: Timothy L. Enns, S.V.P., Corporate Communications & BusinessDevelopment of SuperGen, +1-925-560-0100 ext. 111, email@example.com; orSharon Weinstein, Director of Investor Relations of Noonan Russo,+1-212-845-4271, firstname.lastname@example.org
Web site: http://www.supergen.com/